AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6127888 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 0
Study 31755559 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral uterine artery ligation (BUAL)
Number of subjects: 0
Study 31755559 — intervention group
Group type: COMPARATOR
Intervention: Control (cesarean delivery without BUAL)
Number of subjects: 0
Study 31755559 — intervention group
Group type: COMPARATOR
Intervention: BUAL and Control
Number of subjects: 0
Study 28752645 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure (-150 mmHg)
Number of subjects: 164
Study 28752645 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pressure (-100 mmHg)
Number of subjects: 164
Study 28752645 — intervention group
Group type: COMPARATOR
Intervention: Control (none)
Number of subjects: 164
Study 26395743 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) including weight loss and physical activity
Number of subjects: 3845
Study 26395743 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (Control)
Number of subjects: 3845
Study 24944131 — intervention group
Group type: EXPERIMENTAL
Intervention: Football training group (FTG)
Number of subjects: 41
Study 24944131 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 41
Study 22525561 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endoscopic treatment within 72 hours after initial symptom
Number of subjects: 120
Study 22525561 — intervention group
Group type: COMPARATOR
Intervention: No endoscopic treatment (control group)
Number of subjects: 120
Study 20389025 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of insulin (0.1 IU/kg)
Number of subjects: 18
Study 20389025 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 9)
Number of subjects: 18
Study 18710631 — intervention group
Group type: EXPERIMENTAL
Intervention: Inh‐Ins
Number of subjects: 253
Study 18710631 — intervention group
Group type: COMPARATOR
Intervention: RI
Number of subjects: 253
Study 16834579 — intervention group
Group type: EXPERIMENTAL
Intervention: New admission form
Number of subjects: 100
Study 16834579 — intervention group
Group type: COMPARATOR
Intervention: Old admission form
Number of subjects: 100
Study 12865040 — intervention group
Group type: COMPARATOR
Intervention: Healthy Lifestyle Control
Number of subjects: 316
Study 12865040 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Weight Loss
Number of subjects: 316
Study 12865040 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Exercise
Number of subjects: 316
Study 12865040 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Exercise and Dietary Weight Loss
Number of subjects: 316
Study 11100339 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (n = 58)
Number of subjects: 197
Study 11100339 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy plus octreotide (n = 44)
Number of subjects: 197
Study 11100339 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy (n = 53 for group I; n = 42 for group II)
Number of subjects: 197
Study 8896140 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiotherapy
Number of subjects: 0
Study 8896140 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy followed by cystectomy
Number of subjects: 0
Study 1667298 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fibre diet
Number of subjects: 72
Study 7071350 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chloral hydrate (80 mg/kg)
Number of subjects: 582
Study 7071350 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular preparation (AMPS: atropine, meperidine, promethazine, secobarbital)
Number of subjects: 582
Study 7071350 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal anesthesia
Number of subjects: 582
Study 7071350 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (not specified)
Number of subjects: 582
Study 31286116 — intervention group
Group type: EXPERIMENTAL
Intervention: One Shape
Number of subjects: 99
Study 31286116 — intervention group
Group type: EXPERIMENTAL
Intervention: Revo‐S
Number of subjects: 99
Study 31286116 — intervention group
Group type: EXPERIMENTAL
Intervention: WaveOne
Number of subjects: 99
Study 27822851 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrating-mesh nebulizer combined with a valved holding chamber (Aerogen Ultra®, Aerogen Ltd., Galway, Ireland)
Number of subjects: 6
Study 27822851 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulizer connected to a corrugated tube (Opti‐Mist Plus Nebulizer®, ConvaTec, Bridgewater, NJ)
Number of subjects: 6
Study 26203171 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based drug-treatment and health-education intervention
Number of subjects: 75
Study 24063287 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL)
Number of subjects: 0
Study 24063287 — intervention group
Group type: COMPARATOR
Intervention: Lecture-Based Learning (LBL)
Number of subjects: 0
Study 21931871 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-lasting insecticidal nets (LNs)
Number of subjects: 305
Study 21931871 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LNs)
Number of subjects: 305
Study 19525621 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 2778
Study 19525621 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART after IPT
Number of subjects: 2778
Study 19525621 — intervention group
Group type: COMPARATOR
Intervention: No IPT or HAART
Number of subjects: 2778
Study 19525621 — intervention group
Group type: COMPARATOR
Intervention: HAART without IPT
Number of subjects: 2778
Study 19525621 — intervention group
Group type: COMPARATOR
Intervention: IPT without HAART
Number of subjects: 2778
Study 17192324 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (2-4 mg/day)
Number of subjects: 78
Study 17192324 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (high-dose 8 mg/day)
Number of subjects: 78
Study 17192324 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 78
Study 15051570 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoblotting
Number of subjects: 44
Study 15051570 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 44
Study 15051570 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 44
Study 15051570 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA
Number of subjects: 44
Study 11170976 — intervention group
Group type: EXPERIMENTAL
Intervention: oseltamivir
Number of subjects: 54
Study 11170976 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study 9571357 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate
Number of subjects: 164
Study 7846291 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic treatment alongside practical care, initiated during pregnancy and conducted in mothers' homes on a long-term basis.
Number of subjects: 2
Study 3044800 — intervention group
Group type: EXPERIMENTAL
Intervention: MP
Number of subjects: 320
Study 3044800 — intervention group
Group type: COMPARATOR
Intervention: VCMP
Number of subjects: 320
Study 3044800 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment (induction scheme q 8 weeks)
Number of subjects: 320
Study 3044800 — intervention group
Group type: COMPARATOR
Intervention: No further chemotherapy
Number of subjects: 320
Study 31466276 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised controlled exercise at 8 kcal/kg of body weight/week
Number of subjects: 164
Study 31466276 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised controlled exercise at 20 kcal/kg of body weight/week
Number of subjects: 164
Study 31466276 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164
Study 28783872 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF) 240 mg twice daily
Number of subjects: 46
Study 28783872 — intervention group
Group type: COMPARATOR
Intervention: Combined oral contraceptive (OC; norgestimate 250 μg, ethinyl estradiol 35 μg)
Number of subjects: 46
Study 28783872 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF)
Number of subjects: 46
Study 25557985 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A injected at MEP zones (30% and 60% of the distance from the pubic tubercle to the medial epicondyle)
Number of subjects: 27
Study 25557985 — intervention group
Group type: COMPARATOR
Intervention: BoNT‐A injected proximally (25% of the distance from the pubic tubercle to the medial epicondyle)
Number of subjects: 27
Study 24029542 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin dosing algorithm with daily INR measurements
Number of subjects: 30
Study 21675334 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Goal Intervention (OGI)
Number of subjects: 18
Study 21675334 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal Executive Program
Number of subjects: 18
Study 21675334 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 19465443 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a 30 microg IM once weekly
Number of subjects: 181
Study 19465443 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a 30 microg IM once weekly plus AZA 50 mg orally once daily
Number of subjects: 181
Study 19465443 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a 30 microg IM once weekly plus AZA 50 mg orally once daily plus prednisone 10 mg orally every other day
Number of subjects: 181
Study 19465443 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a plus AZA
Number of subjects: 181
Study 19465443 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a plus AZA and prednisone
Number of subjects: 181
Study 19465443 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 181
Study 19465443 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a alone
Number of subjects: 181
Study 16445446 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof Natural (SN60AT) IOL
Number of subjects: 19
Study 16445446 — intervention group
Group type: COMPARATOR
Intervention: AcrySof single‐piece (SA60AT) IOL
Number of subjects: 19
Study 15031241 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum criterion based model
Number of subjects: 66
Study 15031241 — intervention group
Group type: COMPARATOR
Intervention: Educational outcome model
Number of subjects: 66
Study 11567748 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose diphtheria-tetanus vaccine (dT)
Number of subjects: 0
Study 11567748 — intervention group
Group type: COMPARATOR
Intervention: Standard paediatric dose (DT)
Number of subjects: 0
Study 9562691 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT and VaxSyn
Number of subjects: 30
Study 9562691 — intervention group
Group type: COMPARATOR
Intervention: VaxSyn
Number of subjects: 30
Study 9562691 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT
Number of subjects: 30
Study 9562691 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 in vitro
Number of subjects: 30
Study 7843201 — intervention group
Group type: EXPERIMENTAL
Intervention: Single or multiple doses of natural porcine surfactant (Curosurf)
Number of subjects: 343
Study 7843201 — intervention group
Group type: COMPARATOR
Intervention: Single-dose surfactant treatment
Number of subjects: 343
Study 7843201 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose surfactant treatment
Number of subjects: 343
Study 2894548 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 16
Study 2894548 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 16
Study 31282704 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65g/kg alcohol
Number of subjects: 40
Study 30368541 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 26
Study 30368541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 28514945 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative work-up with addition of the prediction model
Number of subjects: 0
Study 28514945 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative work-up
Number of subjects: 0
Study 28514945 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient reported outcomes measured by BREAST-Q, EORTC-QLQ-C30/BR23 and EQ-5D-5L
Number of subjects: 0
Study 28514945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetic outcome assessed through BCCT.core software
Number of subjects: 0
Study 28514945 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation-induced reaction
Number of subjects: 0
Study 28514945 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment performed
Number of subjects: 0
Study 28514945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological result
Number of subjects: 0
Study 28514945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness
Number of subjects: 0
Study 26347153 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 84496
Study 23478662 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (20 mg, 3 times daily for 12 weeks, followed by 60 mg, 3 times daily for 12 weeks)
Number of subjects: 216
Study 23478662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 23478662 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 216
Study 21186062 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 17
Study 21186062 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 17
Study 18315784 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC (2200 mg/kg orally daily for 5 days, every 3 weeks)
Number of subjects: 21
Study 18315784 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC + CCNU (DTIC at 2200 mg/kg and CCNU at 120 mg/m2 once every 40 days)
Number of subjects: 21
Study 18315784 — intervention group
Group type: COMPARATOR
Intervention: Control healthy volunteers
Number of subjects: 21
Study 17023870 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate 1.25 mg
Number of subjects: 81
Study 17023870 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate 2.5 mg
Number of subjects: 81
Study 17023870 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate 5.0 mg
Number of subjects: 81
Study 17023870 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate 7.5 mg
Number of subjects: 81
Study 17023870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 17023870 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing dose of methylphenidate
Number of subjects: 81
Study 12877375 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured oncology information pack
Number of subjects: 248
Study 12877375 — intervention group
Group type: COMPARATOR
Intervention: Traditional information provided by the department
Number of subjects: 248
Study 11133707 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCE (extracapsular cataract extraction)
Number of subjects: 108
Study 11133707 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus capture
Number of subjects: 108
Study 11133707 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 108
Study 9722817 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) with free treatment for 90 days
Number of subjects: 200
Study 9722817 — intervention group
Group type: COMPARATOR
Intervention: Motivational interviewing (MI) without free treatment
Number of subjects: 200
Study 9722817 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk reduction (RR) with free treatment for 90 days
Number of subjects: 200
Study 9722817 — intervention group
Group type: COMPARATOR
Intervention: Risk reduction (RR) without free treatment
Number of subjects: 200
Study 7987510 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan, 100 mg
Number of subjects: 0
Study 7987510 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous sumatriptan, 6 mg
Number of subjects: 0
Study 7987510 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined subcutaneous and oral administration of sumatriptan
Number of subjects: 0
Study 2498956 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 hours of smokeless tobacco deprivation
Number of subjects: 40
Study 2498956 — intervention group
Group type: COMPARATOR
Intervention: No deprivation (control group)
Number of subjects: 40
Study 2498956 — intervention group
Group type: COMPARATOR
Intervention: Nonchewers (third control group)
Number of subjects: 40
Study 1094787 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylidrin hydrochloride
Number of subjects: 194
Study 1094787 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxuprine hydrochloride
Number of subjects: 194
Study 1094787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 1094787 — intervention group
Group type: COMPARATOR
Intervention: Ethyl alcohol
Number of subjects: 194
Study 31340565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% + 100 mg Tramadol (2 mL)
Number of subjects: 80
Study 31340565 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.5% + 2 mL NaCl 0.9% (placebo)
Number of subjects: 80
Study 26443696 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity strength training at 20% of 1RM combined with partial blood flow restriction (LI + BFR)
Number of subjects: 40
Study 26443696 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40
Study 26443696 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strength training at 80% of 1RM (HI)
Number of subjects: 40
Study 26443696 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity strength training at 20% of 1RM (LI)
Number of subjects: 40
Study 25142277 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training program including dual‐ and multi‐task exercises, three times/week for 12 weeks.
Number of subjects: 96
Study 23239300 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step procedure (laparoscopic cholecystectomy with intraoperative cholangiogram and ERCP if necessary)
Number of subjects: 20
Study 23239300 — intervention group
Group type: COMPARATOR
Intervention: Two-step procedure (preoperative ERCP followed by laparoscopic cholecystectomy)
Number of subjects: 20
Study 21205128 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 0
Study 21205128 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 0
Study 21205128 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg and 1.8 mg
Number of subjects: 0
Study 18461664 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (Healive); 1 dose administered to 108 individuals and 3365 students.
Number of subjects: 4675
Study 18461664 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (Healive); 1 dose administered to 3365 students.
Number of subjects: 4675
Study 18461664 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccination); 115 individuals and 2572 students.
Number of subjects: 4675
Study 16467770 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 31
Study 16467770 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 31
Study 12975572 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual chamber electrograms (both atrial and ventricular)
Number of subjects: 52
Study 12975572 — intervention group
Group type: COMPARATOR
Intervention: Ventricular electrograms alone
Number of subjects: 52
Study 12135299 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 IU) administered preoperatively, with 2 or 3 doses depending on the procedure, along with oral iron for 14 or 21 days.
Number of subjects: 0
Study 12135299 — intervention group
Group type: COMPARATOR
Intervention: Matched historical control patients receiving standard care without epoetin alfa.
Number of subjects: 0
Study 9375348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential exercise day (SEB; at 1000, 1130, and 1300)
Number of subjects: 7
Study 9375348 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed exercise day (DEB; at 1000, 1400, and 1800)
Number of subjects: 7
Study 9375348 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed exercise day (DEB)
Number of subjects: 7
Study 9375348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential exercise day (SEB)
Number of subjects: 7
Study 7902470 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-blockers (Histadyl)
Number of subjects: 0
Study 7902470 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (HBO)
Number of subjects: 0
Study 7902470 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term maintenance therapy with drugs improving local microcirculation and stimulating bicarbonates production in gastric mucosa (synthetic prostaglandins analogues)
Number of subjects: 0
Study 30335135 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavac vaccine (monovalent human-bovine 116E)
Number of subjects: 1169
Study 30335135 — intervention group
Group type: COMPARATOR
Intervention: Presence of coinfections
Number of subjects: 1169
Study 29617381 — intervention group
Group type: EXPERIMENTAL
Intervention: 8g PEG-3350
Number of subjects: 87
Study 29617381 — intervention group
Group type: EXPERIMENTAL
Intervention: 17g PEG-3350
Number of subjects: 87
Study 29617381 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 87
Study 29617381 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG treatment (both doses combined)
Number of subjects: 87
Study 26794725 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 0
Study 26794725 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography
Number of subjects: 0
Study 25208561 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid-rich dark chocolate (50 g)
Number of subjects: 65
Study 25208561 — intervention group
Group type: COMPARATOR
Intervention: Placebo chocolate (50 g)
Number of subjects: 65
Study 21811866 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly ibandronate treatment for 12 months
Number of subjects: 89